Business
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Expects to Commence Phase 2a of CAReS During the First Quarter of 2023 SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.
About this update from Artelo Biosciences, Inc.
[{"type":"text","content":"Expects to Commence Phase 2a of CAReS During the First Quarter of 2023\nSOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) is now complete. The first stage of the CAReS clinical trial is intended to evaluate the safety of ART27.13. Following a review of initial treatment data from the Phase 1b, Artelo expects to select the optimal dose for the randomized Phase 2a stage of CAReS, which is designed to further explore safety and efficacy of ART27.13. “Participants in the fourth and final cohort in the Phase 1b stage of CAReS are being treated at the highest dose allowed by the protocol, 650 micrograms,” said Steven D. Reich, M.D, Chief Medical Officer of Artelo Biosciences. “To date, ART27.13 has been well-tolerated with only mild to moderate adverse reactions attributable to the investigational drug in patients suffering from anorexia associated with cancer. We are highly encouraged by the safety profile thus far, and eagerly await the results of this important study. We anticipate advancing to the Phase 2a stage of the trial after we assess the safety and activity data from the Phase 1b stage.” “We wish to express our gratitude to the patients and the research teams who overcame enrollment challenges, including those attributed to the pandemic, to achieve this enrollment milestone in the CAReS study,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We eagerly anticipate commencing enrollment in the randomized Phase 2a portion of CAReS and look forward to welcoming new sites from additional countries in Europe to join the participating sites in the United Kingdom and Ireland. ART27.13 is a core program in our commitment to developing new treatment options for people living with cancer and complications from anti-cancer therapies.” About ART27.13ART27.13 is a highly potent, peripherally restricted synthetic, dual G-Protein Couple Receptor agonist believed to target the cannabinoid receptors CB1 and CB2, which has the potential to increase appetite and foo...